Allogenetics
Allogenetics GmbH is pioneering a new approach to organ transplantation by creating immunological invisibility of donor organs, eliminating the need for lifelong immunosuppression. Their innovative technology aims to improve graft survival, quality of life for recipients, and increase organ availability.
Industries
Nr. of Employees
small (1-50)
Allogenetics
Feodor-Lynen-Str. 5, 30625 Hanover, Germany
Products
Genetically modified donor lung (clinical Phase 1)
Donor lung candidate genetically modified ex vivo to reduce HLA/MHC antigen expression and evaluated in a clinical Phase 1 study to assess safety and feasibility of transplantation without lifelong immunosuppression.
Genetically modified donor kidney (preclinical)
Preclinical kidney candidate modified ex vivo to reduce immunogenic markers and evaluated in preclinical models for rejection prevention.
Genetically modified donor heart (preclinical)
Heart candidate undergoing preclinical development to apply organ-level genetic modification for reduced immunogenicity prior to transplantation.
Genetically modified donor liver (discovery)
Early discovery-stage program to explore genetic modification approaches for liver grafts to reduce immunological recognition.
Genetically modified donor lung (clinical Phase 1)
Donor lung candidate genetically modified ex vivo to reduce HLA/MHC antigen expression and evaluated in a clinical Phase 1 study to assess safety and feasibility of transplantation without lifelong immunosuppression.
Genetically modified donor kidney (preclinical)
Preclinical kidney candidate modified ex vivo to reduce immunogenic markers and evaluated in preclinical models for rejection prevention.
Genetically modified donor heart (preclinical)
Heart candidate undergoing preclinical development to apply organ-level genetic modification for reduced immunogenicity prior to transplantation.
Genetically modified donor liver (discovery)
Early discovery-stage program to explore genetic modification approaches for liver grafts to reduce immunological recognition.
Expertise Areas
- Transplant engineering
- Organ preservation and ex vivo perfusion
- Organ genetic modification to reduce immunogenicity
- Cell and gene therapy R&D
Key Technologies
- Viral vector-mediated gene delivery
- Ex vivo normothermic organ perfusion
- HLA/MHC gene silencing
- Transgene expression for organ protection
News & Updates
Allogenetics is the winner of this year's DurchSTARTer-Preis in the Life Science category, recognizing their innovative approach to solving organ rejection after transplantation.
Allogenetics was announced as the winner in the Life Science category of the DurchSTARTer-Preis 2022, an award honoring innovative startups from Lower Saxony.
Allogenetics was a finalist in the DurchSTARTer award in 2022, recognized for their innovative approach to organ transplantation.
Allogenetics is the winner of this year's DurchSTARTer-Preis in the Life Science category, recognizing their innovative approach to solving organ rejection after transplantation.
Allogenetics was announced as the winner in the Life Science category of the DurchSTARTer-Preis 2022, an award honoring innovative startups from Lower Saxony.
Allogenetics was a finalist in the DurchSTARTer award in 2022, recognized for their innovative approach to organ transplantation.